BOSTON--(BUSINESS WIRE)--Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, today announced that Brad Margus, Chief Executive Officer, will present the company’s target discovery and clinical development work during the 2019 BIO Investor Forum taking place October 22nd-23rd, 2019 in San Francisco, CA.
Date: Tuesday, October 22, 2019
Time: 2 p.m. PT
Location: The Westin St. Francis
Room: Elizabethan A (2nd Floor)
The BIO Investor Forum is an international biotech investor conference focused on early and established private companies, as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and BIO One-on-One Partnering™ meetings.
Cerevance is a private pharmaceutical company focused on central nervous system diseases. The company’s powerful NETSseq target discovery platform is being applied to a growing collection of more than 6,000 human brain tissue samples, yielding a pipeline of novel discovery-stage and clinical-stage compounds. With a proven track record, Cerevance’s team believes it is well positioned to deliver life-changing therapeutics for patients who have brain-related disorders.